Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab PK/PD in Japanese Healthy Volunteers
NCT04765553Phase 1Completed
- Sponsor
- Sobi
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hemophagocytic lymphohistiocytosis (HLH) comparing Emapalumab with Placebo (2 arms). Primary endpoints: Maximum Observed Concentration of Emapalumab, Time to Maximum Concentration of Emapalumab and 6 more. Started Jan 2021; status: completed.
02
Drugs
emapalumab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT04765553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765553.